Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track APLM with free AI briefings, catalyst countdowns, and dilution alerts.

APLM · Apollomics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.3M Cash on Hand
3.8mo Cash Runway
Follow APLM by email Get an email when APLM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APLM, unsubscribe in one click. Privacy

📣 What APLM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Uproleselan Relapsed/Refractory AML Phase 3 · NCT05054543 Terminated
Vebreltinib (APL-101) Metastatic Non Small Cell Lung Cancer Phase 1/2 · NCT04743505 Active not recruiting
Geptanolimab (APL-501) Hepatocellular Carcinoma Phase 1/2 · NCT03655613 Terminated
Osimertinib Metastatic Non Small Cell Lung Cancer Phase 1/2 · NCT04743505 Active not recruiting
APL-102 Capsules Advanced Solid Tumor Phase 1 · NCT05055518 Suspended

Also used in these trials (approved or third-party drugs, not APLM's own candidates): Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APLM holds $3.3M in cash and short-term investments and burns about $2.6M/quarter from operations, an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 85 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APLM files for a raise →

👥 Who Owns APLM

Insiders 75.6% Institutions (6 holders) 0.4% Public and other holders 24%
HolderTypeShares% of sharesAs of
Hung-Wen Chen
Chief Executive Officer, Director, 10% o · +13,000 options
Insider 1,453,029 66.17% 2026-09-14
Yi-Kuei Chen
Chief Operating Officer, Director · +13,000 options
Insider 141,348 6.44% 2026-09-14
Peter Kuan-how Lin
Chief Financial Officer · +16,000 options
Insider 55,563 2.53% 2026-09-14
Hong-jung Chen
Director · +2,500 options
Insider 4,120 0.19% 2026-09-14
Hsien-shu Tsai
Director · +2,500 options
Insider 2,000 0.09% 2026-09-14
Ya-Chi Huang
Director · +2,500 options
Insider 1,500 0.07% 2026-08-17
Yi-an Chu
Director · +500 options
Insider 1,500 0.07% 2026-06-15
Chen-Huan Jan
Director · +500 options
Insider 1,500 0.07% 2026-06-15
Hung Hsien Yen
Director · +2,500 options
Insider 500 0.02% 2026-09-14

Share count 2,196,052 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full APLM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APLM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.